akhatri

As part of our Funding & Reimbursement Shorts series, Community Pharmacy England’s in-house Drug Tariff experts have created a new video discussing the structure of the Drug Tariff. In this video, we provide guidance on the different parts of Part VIII of the Drug Tariff, with a particular focus on Part VIIIA. In this video, Mitesh [...]

The post Funding & Reimbursement Shorts: Part VIII of the Drug Tariff appeared first on Community Pharmacy England.

Following the introduction of Category H in March 2026, the Department of Health and Social Care (DHSC) has announced that the following 8 products will move from Category C to Category H, effective from September 2026: Alfuzosin 10mg modified-release tablets Diclofenac 100mg suppositories Felodipine 10mg modified-release tablets Felodipine 2.5mg modified-release tablets Felodipine 5mg modified-release tablets [...]

The post Advance notice of 8 products moving to Category H in September 2026 appeared first on Community Pharmacy England.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for: Diclofenac (Voltarol® Ophtha) 0.1% eye drops 0.3ml unit dose preservative-free and; Diclofenac (Voltarol® Ophtha Multidose) 0.1% eye drops MSN/2026/034 Tier 2 – medium impact Date of issue: 30 July 2026 Various brands and strengths of nifedipine modified-release tablets are experiencing supply [...]

The post Medicine Supply Notification: Voltarol® Ophtha and Voltarol® Ophtha Multidose eye drops appeared first on Community Pharmacy England.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Nifedipine 10mg, 20mg, 30mg and 60mg modified-release tablets. MSN/2026/033 Tier 2 – medium impact Date of issue: 23 July 2026 Various brands and strengths of nifedipine modified-release tablets are experiencing supply issues: Tensipine® MR 10 and 20 tablets will be out [...]

The post Medicine Supply Notification: Nifedipine 10mg, 20mg, 30mg and 60mg modified-release tablets appeared first on Community Pharmacy England.

MHRA Drug Safety Update: Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension. The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episodes of severe hypertension. [...]

The post MHRA Drug Safety Update: Domperidone new contraindication appeared first on Community Pharmacy England.